WorldWide Antimalarial Resistance Network

WorldWide Antimalarial Resistance Network
Name	WorldWide Antimalarial Resistance Network
Founded	2009
Focus	Malaria drug efficacy and resistance surveillance
Headquarters	Oxford, United Kingdom
Key people	Nicholas J. White, Philippe J. Guerin
Website	www.wwarn.org

WorldWide Antimalarial Resistance Network. It is a global collaborative scientific platform established to coordinate the tracking and response to antimalarial drug resistance. The network aggregates and standardizes data from clinical, pharmacological, and molecular studies to provide a comprehensive evidence base. Its work is crucial for informing World Health Organization treatment guidelines and supporting national malaria control programmes worldwide.

History and establishment

The network was formally launched in 2009, emerging from growing international concern over the spread of resistance to artemisinin-based combination therapies. Its creation was driven by a consortium of leading malaria researchers, including Nicholas J. White of Mahidol University and Philippe J. Guerin, with foundational support from the Bill & Melinda Gates Foundation. The initiative built upon lessons learned from historical resistance to earlier drugs like chloroquine and sulfadoxine/pyrimethamine, which devastated regions such as Southeast Asia and Sub-Saharan Africa. The establishment was strategically aligned with the broader goals of the Roll Back Malaria Partnership and received endorsement from the World Health Organization.

Objectives and mission

Its primary mission is to ensure that antimalarial treatments remain effective by detecting and containing resistance as early as possible. Key objectives include standardizing methodologies for monitoring parasite genotype and phenotype, establishing quality-assured global databases, and developing practical tools for field epidemiology. The network aims to translate complex research data into actionable intelligence for policymakers at institutions like the Centers for Disease Control and Prevention and ministries of health in endemic countries. Ultimately, it seeks to prolong the therapeutic life of existing drugs and guide the development of new antimalarial medication.

Structure and governance

The network operates as a decentralized collaboration, coordinated by a central hub based at the University of Oxford. Governance is provided by a Steering Committee comprising experts from institutions like the Institut Pasteur, Médecins Sans Frontières, and various National Institute of Allergy and Infectious Diseases-funded research units. Scientific oversight is managed through specialized working groups focusing on areas such as clinical trials, pharmacology, and molecular markers. This structure facilitates partnerships with regional networks in Asia, Africa, and South America, ensuring representation from key endemic zones.

Key activities and research

Core activities involve conducting systematic reviews and individual participant data meta-analyses on drug efficacy. The network has pioneered research into molecular markers of resistance, notably for genes associated with artemisinin and partner drug failure like the *kelch13* propeller region. It develops and validates standardized in vitro and in vivo protocols, which are used in surveillance studies from the Greater Mekong Subregion to the Sahel. The network also investigates the impact of factors such as pregnancy, HIV co-infection, and malnutrition on treatment outcomes.

Data sharing and surveillance

A cornerstone of its work is the Antimalarial Resistance Data Repository, a curated, open-access database that complies results from published and unpublished studies. The network advocates for and practices rigorous FAIR data principles to ensure interoperability. It provides online tools, such as the PCR Correction Tool and the Parasite Clearance Estimator, to aid surveillance activities by entities like the Armed Forces Research Institute of Medical Sciences and the African Centre for Disease Control. This system enables near real-time mapping of resistance threats, similar to frameworks used for influenza or antimicrobial resistance.

Impact and significance

The network has directly influenced global policy, providing the evidence base for updates to the World Health Organization's *Guidelines for the Treatment of Malaria*. Its surveillance data were instrumental in documenting and responding to the emergence of artemisinin resistance in Cambodia and Myanmar. By fostering unprecedented collaboration between groups like the MalariaGEN Consortium and national programmes, it has strengthened regional capacity for drug resistance monitoring. Its model is considered a blueprint for addressing other emerging threats of infectious disease drug resistance.

Category:Medical research organizations Category:Malaria Category:Organizations established in 2009